Literature DB >> 17089404

Schimke immunoosseous dysplasia: suggestions of genetic diversity.

J Marietta Clewing1, Helen Fryssira, David Goodman, Sarah F Smithson, Emily A Sloan, Shu Lou, Yan Huang, Kunho Choi, Thomas Lücke, Harika Alpay, Jean-Luc André, Yumi Asakura, Nathalie Biebuyck-Gouge, Radovan Bogdanovic, Dominique Bonneau, Caterina Cancrini, Pierre Cochat, Sandra Cockfield, Laure Collard, Isabel Cordeiro, Valerie Cormier-Daire, Karlien Cransberg, Karel Cutka, Georges Deschenes, Jochen H H Ehrich, Stefan Fründ, Helen Georgaki, Encarna Guillen-Navarro, Barbara Hinkelmann, Maria Kanariou, Belde Kasap, Sara Sebnem Kilic, Guiliana Lama, Petra Lamfers, Chantal Loirat, Silvia Majore, David Milford, Denis Morin, Nihal Ozdemir, Bertram F Pontz, Willem Proesmans, Stavroula Psoni, Herbert Reichenbach, Silke Reif, Cristina Rusu, Jorge M Saraiva, Onur Sakallioglu, Beate Schmidt, Lawrence Shoemaker, Sabine Sigaudy, Graham Smith, Flora Sotsiou, Natasa Stajic, Anja Stein, Asbjørg Stray-Pedersen, Doris Taha, Sophie Taque, Jane Tizard, Michel Tsimaratos, Newton A C S Wong, Cornelius F Boerkoel.   

Abstract

Schimke immunoosseous dysplasia (SIOD), which is characterized by prominent spondyloepiphyseal dysplasia, T-cell deficiency, and focal segmental glomerulosclerosis, is a panethnic autosomal recessive multisystem disorder with variable expressivity. Biallelic mutations in switch/sucrose nonfermenting (swi/snf) related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1 (SMARCAL1) are the only identified cause of SIOD. However, among 72 patients from different families, we identified only 38 patients with biallelic mutations in the coding exons and splice junctions of the SMARCAL1 gene. This observation, the variable expressivity, and poor genotype-phenotype correlation led us to test several hypotheses including modifying haplotypes, oligogenic inheritance, or locus heterogeneity in SIOD. Haplotypes associated with the two more common mutations, R820H and E848X, did not correlate with phenotype. Also, contrary to monoallelic SMARCAL1 coding mutations indicating oligogenic inheritance, we found that all these patients did not express RNA and/or protein from the other allele and thus have biallelic SMARCAL1 mutations. We hypothesize therefore that the variable expressivity among patients with biallelic SMARCAL1 mutations arises from environmental, genetic, or epigenetic modifiers. Among patients without detectable SMARCAL1 coding mutations, our analyses of cell lines from four of these patients showed that they expressed normal levels of SMARCAL1 mRNA and protein. This is the first evidence for nonallelic heterogeneity in SIOD. From analysis of the postmortem histopathology from two patients and the clinical data from most patients, we propose the existence of endophenotypes of SIOD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17089404     DOI: 10.1002/humu.20432

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  23 in total

1.  An unusual cause of nephrotic syndrome: Answers.

Authors:  Zeynep Yuruk Yildirim; Melis Ozkan; Alev Yilmaz; Hülya Kayserili; Cemile Pehlivanoglu; Sevinc Emre; Ahmet Nayir
Journal:  Pediatr Nephrol       Date:  2018-11-07       Impact factor: 3.714

Review 2.  Functions of SMARCAL1, ZRANB3, and HLTF in maintaining genome stability.

Authors:  Lisa A Poole; David Cortez
Journal:  Crit Rev Biochem Mol Biol       Date:  2017-09-28       Impact factor: 8.250

3.  A novel splice site mutation in SMARCAL1 results in aberrant exon definition in a child with Schimke immunoosseous dysplasia.

Authors:  Clinton Carroll; Tracy E Hunley; Yan Guo; David Cortez
Journal:  Am J Med Genet A       Date:  2015-05-05       Impact factor: 2.802

Review 4.  Bone marrow transplantation in Schimke immuno-osseous dysplasia.

Authors:  Alireza Baradaran-Heravi; Jonas Lange; Yumi Asakura; Pierre Cochat; Laura Massella; Cornelius F Boerkoel
Journal:  Am J Med Genet A       Date:  2013-08-15       Impact factor: 2.802

5.  Chromatin changes in SMARCAL1 deficiency: A hypothesis for the gene expression alterations of Schimke immuno-osseous dysplasia.

Authors:  Marie Morimoto; Kunho Choi; Cornelius F Boerkoel; Kyoung Sang Cho
Journal:  Nucleus       Date:  2016-11       Impact factor: 4.197

6.  Dental abnormalities and preventive oral care in Schimke immuno-osseous dysplasia.

Authors:  M Gendronneau; O Kérourédan; S Taque; J L Sixou; M Bonnaure-Mallet
Journal:  Eur Arch Paediatr Dent       Date:  2013-12-11

7.  SMARCAL1 deficiency predisposes to non-Hodgkin lymphoma and hypersensitivity to genotoxic agents in vivo.

Authors:  Alireza Baradaran-Heravi; Anja Raams; Joanna Lubieniecka; Kyoung Sang Cho; Kristi A DeHaai; Mitra Basiratnia; Pierre-Olivier Mari; Yutong Xue; Michael Rauth; Ann Haskins Olney; Mary Shago; Kunho Choi; Rosanna A Weksberg; Malgorzata J M Nowaczyk; Weidong Wang; Nicolaas G J Jaspers; Cornelius F Boerkoel
Journal:  Am J Med Genet A       Date:  2012-08-07       Impact factor: 2.802

8.  Novel SMARCAL1 bi-allelic mutations associated with a chromosomal breakage phenotype in a severe SIOD patient.

Authors:  Amos J Simon; Atar Lev; Marta Jeison; Zvi U Borochowitz; David Korn; Yaniv Lerenthal; Raz Somech
Journal:  J Clin Immunol       Date:  2013-11-07       Impact factor: 8.317

9.  Clinical and genetic distinction of Schimke immuno-osseous dysplasia and cartilage-hair hypoplasia.

Authors:  Alireza Baradaran-Heravi; Christian Thiel; Anita Rauch; Martin Zenker; Cornelius F Boerkoel; Ilkka Kaitila
Journal:  Am J Med Genet A       Date:  2008-08-01       Impact factor: 2.802

10.  Schimke immunoosseous dysplasia: defining skeletal features.

Authors:  Kshamta B Hunter; Thomas Lücke; Jürgen Spranger; Sarah F Smithson; Harika Alpay; Jean-Luc André; Yumi Asakura; Radovan Bogdanovic; Dominique Bonneau; Robyn Cairns; Karlien Cransberg; Stefan Fründ; Helen Fryssira; David Goodman; Knut Helmke; Barbara Hinkelmann; Guiliana Lama; Petra Lamfers; Chantal Loirat; Silvia Majore; Christy Mayfield; Bertram F Pontz; Cristina Rusu; Jorge M Saraiva; Beate Schmidt; Lawrence Shoemaker; Sabine Sigaudy; Natasa Stajic; Doris Taha; Cornelius F Boerkoel
Journal:  Eur J Pediatr       Date:  2009-12-15       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.